Inhibition of cell growth and potentiation of tumor necrosis factor-α (TNF-α)-induced apoptosis by a phenanthroindolizidine alkaloid antofine in human colon cancer cells

Biochemical Pharmacology

Volumn 80, Issue 9, 2010, Pages 1356-1364

  Min, Hye Young ^a   Chung, Hwa Jin ^a,b   Kim, Eun Hye ^a   Kim, Sanghee ^b   Park, Eun Jung ^a   Lee, Sang Kook ^a,b  

^a Ewha Womans University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Anti proliferation; Antitumor; Antofine; Phenanthroindolizidine alkaloid

Indexed keywords

ANTOFINE; BETA CATENIN; CAMPTOTHECIN; CASPASE 8; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN E; INDOLIZIDINE ALKALOID; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; T CELL FACTOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINBLASTINE; WNT PROTEIN; INDOLE DERIVATIVE; PHENANTHROLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL POPULATION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; CYNANCHUM; CYNANCHUM PANICULATUM; DNA SYNTHESIS; DRUG IDENTIFICATION; DRUG ISOLATION; FEMALE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; CELL CYCLE; COLONIC NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; INDOLES; MICE; MICE, INBRED BALB C; PHENANTHROLINES; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; WNT PROTEINS;

EID: 77956630631     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.07.026     Document Type: Article

References (29)

1. Gellert E. The indolizidine alkaloids. J Nat Prod 1982, 45:50-73.
2. Komatsu H., Watanabe M., Ohyama M., Enya T., Koyama K., Kanazawa T., et al. Phenanthroindolizidine alkaloids as cytotoxic substances in a Danaid butterfly, Ideopsis similis, against human cancer cells. J Med Chem 2001, 44:1833-1836.
3. Stærk D., Lykkeberg A.K., Christensen J., Budnik B.A., Abe F., Jaroszewski J.W. In vitro cytotoxic activity of phenanthroindolizidine alkaloids from Cynanchum vincetoxicum and Tylophora tanakae against drug-sensitive and multidrug-resistant cancer cells. J Nat Prod 2002, 65:1299-1302.
4. Gao W., Lam W., Zhong S., Kaczmarek C., Baker D.C., Cheng Y.C. Novel mode of action of tylophorine analogs as antutmor compounds. Cancer Res 2004, 64:678-688.
5. Huang M.T., Grollman A.P. Mode of action of tylocrebine: effects on protein and nucleic acid synthesis. Mol Pharmacol 1972, 8:538-550.
6. Rao K.N., Venkatachalam S.R. Inhibition of dihydrofolate reductase and cell growth activity by the phenanthroindolizidine alkaloids pergularinine and tylophoridine: the in vitro cytotoxicity of these plant alkaloids and their potential an antimicrobial and anticancer agents. Toxicol In Vitro 2000, 14:53-59.
7. Ganguly T., Khar A. Induction of apoptosis in a human erythroleukemic cell line K562 by Tylophora alkaloids involves release of cytochrome c and activation of caspase 3. Phytomedicine 2002, 9:288-295.
8. Xi Z., Zhang R., Yu Z., Ouyang D., Huang R. Selective interaction between tylophorine B and bulged DNA. Bioorg Med Chem Lett 2005, 15:2673-2677.
9. Shiah H.S., Gao W., Baker D.C., Cheng Y.C. Inhibition of cell growth and nuclear factor-κB activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503. Mol Cancer Ther 2006, 5:2484-2493.
10. Capo M., Saa J.M. (-)-Antofine: a phenanthroindolizidine from Vincetoxicum nigrum. J Nat Prod 1989, 52:389-390.
11. Nam K.A., Heo Y.H., Lee S.K. Cytotoxic activity and G2/M cell cycle arrest mediated by antofine, a phenanthroindolizidine alkaloid isolated from Cynanchum paniculatum. Planta Med 2003, 69:21-25.
12. Nam K.A., Lee S.K. Evaluation of cytotoxic potential of natural products in cultured human cancer cells. Nat Prod Sci 2000, 6:183-188.
13. Fu Y., Lee S.K., Min H.Y., Lee T., Lee J., Cheng M., et al. Synthesis and structure-activity studies of antofine analogues as potential anticancer agents. Bioorg Med Chem Lett 2007, 17:97-100.
14. Kim S., Lee J., Lee T., Park H.G., Kim D. First asymmetric total synthesis of (-)-antofine by using an enantioselective catalytic phase transfer alkylation. Org Lett 2003, 5:2703-2706.
15. Kim S., Lee T., Lee E., Lee J., Fan G.J., Lee S.K., et al. Asymmetric total syntheses of (-)-antofine and (-)-cryptopleurine using (R)-(E)-4-(Tributylstannyl) but-3-en-2-ol. J Org Chem 2004, 69:3144-3149.
16. Szakács G., Paterson J.K., Ludwig J.A., Booth-Centhe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5:219-234.
17. Willingham M.C. Cytochemical methods for the detection of apoptosis. J Histochem Cytochem 1994, 47:1101-1109.
18. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006, 24:1770-1783.
19. Giles R.H., van Es J.H., Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003, 1653:1-24.
20. -/- colon carcinoma. Science 1997, 275:1784-1787.
21. Ilyas M., Tomlinson I.P.M., Rowan A., Pignatelli M., Bodmer W.F. β-Catenin mutations in cell lines established from human colorectal cancers. Proc Natl Sci Acad USA 1997, 94:10330-10334.
22. van Horssen R., Ten Hagen T.L.M., Eggermont A.M.M. TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility. The Oncologist 2006, 11:397-408.
23. Aggarwal B.B. Signaling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003, 3:745-756.
24. Gao W., Chen A.P.C., Leung C.H., Gullen E.A., Fürstner A., Shi Q., et al. Structural analogs of tylophora alkaloids may not be functional analogs. Bioorg Med Chem Lett 2008, 18:704-709.
25. Sakamaki T., Casimiro M.C., Ju X., Quong A.A., Katiyar S., Liu M., et al. Cyclin D1 determines mitochondrial function in vivo. Mol Cell Biol 2006, 26:5449-5469.
26. Kawada M., Seno H., Uenoyama Y., Sawabu T., Kanda N., Fukui H., et al. Signal transducers and activators of transcription 3 activation is involved in nuclear accumulation of β-catenin in colorectal cancer. Cancer Res 2006, 66:2913-2917.
27. LeBlanc H., Lawrence D., Varfolomeev E., Totpal K., Morlan J., Schow P., et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002, 8:274-281.
28. Nio Y., Zighelboim J., Berek J., Bonavida B. Cycloheximide-induced modulation of TNF-mediated cytotoxicity in sensitive and resistant ovarian tumor cells. Cancer Chemother Pharmacol 1990, 26:1-8.
29. Brown-Bryan T.A., Leoh L.S., Ganapathy V., Pacheco F.J., Mediavilla-Varela M., Filippova M., et al. Alternative splicing and caspase-mediated cleavage generate antagonistic variants of the stress oncoprotein LEDGF/p75. Mol Cancer Res 2008, 6:1293-1307.